EXHIBIT 10.24  REDACTED VERSION  CLINICAL SUPPLY AGREEMENT  This agreement (the Agreement) is entered into
effective as of December 1, 2001by and between The Curators of The University of
Missouri, a public corporation of the State of Missouri, contracting on behalf
of its Research Reactor Center, University of Missouri-Columbia (hereafter
University), and NeoRx Corporation, a Washington corporation (NeoRx).  University and NeoRx may hereafter from time
to time be referred to collectively as the Parties and individually as a
Party.  WITNESSETH  WHEREAS, NeoRx has obtained the rights to use certain
technology and processes to make, use, sell and distribute certain
radiopharmaceutical products for clinical and commercial purposes; and  WHEREAS, University owns facilities and has technical
expertise to produce radioisotopes, which are necessary for NeoRx to produce
its radiopharmaceutical products; and  WHEREAS, NeoRx desires that University manufacture and
supply to and on behalf of NeoRx certain quantities of reactor-produced
radioisotopes in radiochemical form from University, and University is willing
and able to provide such radioisotopes to and on behalf of NeoRx, all in
accordance with the terms and conditions set forth in this Agreement;  NOW THEREFORE, in consideration of the foregoing
promises and agreements set forth herein, the Parties agree as follows:  ARTICLE I - DEFINITIONS  1.1           Affiliate
of a Party means any corporation or other business entity controlled by,
controlling or under common control with such Party.  For this purpose, control means direct or indirect beneficial
ownership of fifty percent (50%) or more of the voting and income interest in
such corporation or other business entity.  1.2           Batch
means a specific quantity of the product intended to have uniform character and
quality and produced according to a single manufacturing order during the same
cycle of manufacture.  1.3           Batch
Record means a QA approved copy of the Master Batch Record used for the
execution of the processing of a specific Batch.  1 
   1.4           Calibration
Time means 12 Noon CST the day of manufacture of the Product.  1.5           Certificate
of Analysis means a written certificate produced by University verifying that
a Batch of the Product was Processed in accordance with the Master Batch Record
and meets the Release Specifications.  1.6           cGMP
means the good manufacturing practices required by the FDA and set forth in the
FD&C Act or FDA regulations, policies, or guidelines in effect at a
particular time for the manufacture, testing and quality control of
radiochemicals to be further processed into a radiopharmaceutical drug product.  1.7           Curie
or Ci is a radioactivity measure as defined in general scientific
literature.  All references to Curies or
Ci amounts are stated in terms of Calibration Time unless otherwise specified.  1.8           Effective
Date means the date this Agreement is entered into, as indicated in the first
paragraph of this Agreement.  1.9           Facility
means Universitys manufacturing facility located at Research Reactor Center,
University of Missouri-Columbia.  1.10         FDA
means the United States Federal Food and Drug Administration and any successor
agency.  1.11         Initial
Payment has the meaning as set forth in Section 4.1.  1.12         Investigational
New Drug or IND means an application document filed with the FDA defining an
investigational new drug product for human use.  1.13         Lot
File means the written record of the Process methodology and testing results
related thereto of a specific Batch of Product ordered pursuant to a Purchase
Order.  The Lot File serves as the
official documentation of the Process and tests performed by University for the
specific Batch of Product.  1.14         Master
File or MF means the Master File dossier prepared by University and filed
with the FDA, which provides the FDA with specific (and proprietary) chemistry,
manufacturing and controls information associated with the Process and the
Facility.  University grants to NeoRx
permission to reference Universitys MF in NeoRxs regulatory filings with the
FDA pertaining to the Product.  1.15         Master
Batch Record means the document, to be created by University, which sets forth
the methodology and formulae for Processing the Product.  1.16         Minimum
Production Capacity has the meaning as set forth in Section 2.5.  1.17         MURR
means the Missouri University Research Reactor, which is a research center
within University.  2 
   1.18         New
Drug Application or NDA means the application for marketing a new drug
product filed with the FDA.  1.19         Process,
Processing, and Processed shall have comparable meanings and mean the act
of manufacturing, handling, testing, storing, analyzing, packaging, inspecting,
labeling and shipping Product in accordance with the Master Batch Record,
Release Specifications and Standard Operating Procedures.  1.20         Product
means Holmium (166) Chloride Processed in accordance with this Agreement.  1.21         Proprietary
Information means all information concerning a Party (the Disclosing Party)
which is furnished to or created by (such as notes, analysis, compilations,
studies, interpretations or other documents) the other Party or its directors,
officers, employees, agents, advisors or Affiliates (collectively, the
Receiving Party) as a result of entering into this Agreement and in
furtherance hereof.  The term
Proprietary Information, however, shall not include information which:  (a)           is
in the public domain or becomes generally available to the public through no
fault of either Party; or  (b)           the
Receiving Party can show by documentary evidence was within its possession or
control prior to its being furnished to the Receiving Party by or on behalf of
the Disclosing Party pursuant hereto, free of any obligation of
confidentiality; or  (c)           the
Receiving Party can show by documentary evidence that came into its possession
or control subsequent to the date of this Agreement from a third party free of
any obligation of confidentiality; or  (d)           was
independently developed by the Receiving Party without the aid, application or
use of the Proprietary Information; or  (e)           is
required to be disclosed by law or order of any governmental authority of
competent jurisdiction (provided, that in such event, the Receiving Party shall
provide the Disclosing Party with notice of such law or order and provide
reasonable cooperation in connection with any attempt to challenge or limit the
scope of such disclosure).  1.22         Purchase
Order means the definitive ordering document originated by NeoRx that sets
forth the quantity of Product ordered and the delivery information.  1.23         Release
Specifications means the set of analytical tests, methods,  and acceptance criteria for Product
attributes which must be met in order to prove the Product meets the standards
of quality, purity, identity and strength filed with the FDA for this
substance.  Release Specifications are a
critical part of the Process and are filed with the FDA as part of an IND, MF
or an NDA.  All Release Specifications
are set forth on Exhibit A attached hereto, which were established initially by
NeoRx in consultation with University and which may be amended from time to time
by written agreement of the Parties and to conform with all  3 
   requirements of the FDA and applicable laws and regulations.  Upon such amendment, University will
implement any modified documents and/or procedures pertinent to the revised
Release Specifications.  1.24         Standard
Operating Procedures or SOPs means universitys internal written standard
operating procedures, designed by University, governing all aspects of
Processing the Product, conducting analytical tests of Product, and maintaining
records related thereto.  1.25         Term
has the meaning as set forth in Section 10.1.  1.26         Waste
means all (a) rejected or unusuable Product, (b) Product not taken  for delivery by NeoRx, for whatever reason,
and (c) waste relating to Universitys Processing of Product.  ARTICLE II- MANUFACTURE & SALE OF PRODUCT  2.1          Equipment  2.1.1       Installation  The Parties acknowledge that University must  maintain in the Facility sufficient
dedicated equipment and associated components (the Dedicated Equipment) to
produce product.  2.1.2       Exclusivity  (a)           During
the Term, University may not use the Dedicated Equipment for any purpose other
than cGMP compatible processing of Holmium 166.  (b)           During
the Term, University grants to NeoRx the first right to the Holmium 166
production capacity at the University.  2.2          Purchase and Sale of Product  University shall Process and sell to NeoRx, and NeoRx
shall purchase from University, during the Term, such quantities of the Product
as NeoRx may from time to time order from University.  University shall Process the Product in strict conformity with
this Agreement, including without limitation the Master Batch Record, Standard
Operating Procedures, Release Specifications and all applicable laws and
regulations.  2.3          Orders and Fulfillment  (a)           Purchase
Orders.  NeoRx shall deliver to
University a written or electronic Purchase Order for the number of Curies that
NeoRx desires to purchase no later than fourteen (14) days prior to the date of
shipment from University.  Each Curie
shall be shipped in such manner, and to such location, as requested by NeoRx in
each Purchase Order, provided University is legally able to do so.  Shipment time shall be as mutually agreed,
but University  4 
   agrees to make its best efforts to work toward an 8:00 a.m. (central
time) shipment time for one Type B cask to Denton, Texas each Monday.  (b)           Additional
Provisions in Purchase Orders.  To
the extent any Purchase Order, invoice or acknowledgement form contains any
provisions additional or contrary to the provisions of this Agreement, such
additional or contrary provision shall have no force or effect and the terms of
this Agreement shall control unless otherwise agreed in writing by the Parties.  (c)           During
the Term, NeoRx agrees to purchase at least 80% of its U.S. Product
requirements from the University to the extent that the University can supply
these needs.  (d)           Notice
of Inability to Fulfill.  University
shall notify NeoRx by telephone and in writing immediately if University
acquires any information that it will not be able to either (i) fulfill the
then most recent Purchase Orders or (ii) maintain Minimum Production
Capacity.  University shall promptly notify
NeoRx by telephone and in writing of any other production issues (including any
proposed or potential shutdown of the Facility for any reason) or other
information of which University becomes aware that may affect the regulatory
status of the Product or the ability of University to supply Product in
accordance with this Agreement or any Purchase Orders.  For planned, extended reactor shutdowns of
greater than one week, the University shall notify NeoRx as soon as the
shutdown is scheduled but in no case less than 90 days prior to the scheduled
shutdown.  For shutdowns of one weeks
duration or less, University shall notify NeoRx as soon as possible.  2.4          NeoRxs Minimum Purchases  In consideration for Universitys processing the Product pursuant to
this Agreement, NeoRx shall pay to University amounts to purchase the Product
based on clause (a) below, unless the parties mutually agree to increase
the  monthly fees and capacity
requirements pursuant to clause (b) or agree to shift the payment structure to
that described in clause (c) as follows:  (a)           Minimum
Monthly Fee.   From  the Effective Date through the termination
of this Agreement, unless the parties earlier agree in writing to the increases
described in clause (b) or shift to the payment structure described in clause
(c), NeoRx shall pay to the University [*]
per month for its readiness to serve (the Minimum Monthly Fee).  This Minimum Monthly Fee (i) obligates the
University to be prepared to Process the Minimum Production Capacity described
in Section 2.5(a) and (ii) also covers the cost of the first 120 Curies
(measured at shipping time) of Product per month.  [*] 
designates portions of this document that have been omitted pursuant to
a request for confidential treatment filed separately with the Commission.  (b)           Increase
in Minimum Monthly Fee.  At any time
during the Term of this Agreement, the parties may mutually agree in writing to
increase the Minimum Monthly Fee in multiples of [*], with each incremental [*]
increase resulting in a corresponding increase of the Minimum Production
Capacity (defined in Section 2.5(a)) in an amount equal to 10 Ci per
batch.  Each agreed upon increase in the
Minimum Monthly Fee and Minimum Production Capacity  5 
   shall be effective through the Term of this Agreement, unless the
parties otherwise agree to (i) increase such fee and capacity as described,
(ii) reduce such fee and capacity in amounts as the parties agree, or (iii)
shift to the payment structure described in the following clause (c).  As an example, for illustration purposes only, the
parties could agree to increase the Minimum Monthly Fee by [*], which would result in the Minimum
Production Capacity being increased by 20 Ci per batch (i.e., to 80 Ci per
batch).  This increased Minimum Monthly
Fee would cover the cost of the first 160 Ci (measured at shipping time) of
product.  The parties could thereafter,
at any time during the Term of this Agreement, (i) again agree to increase the
Minimum Monthly Fee with a corresponding increase in the Minimum Production
Capacity, (ii) reduce the fee and capacity requirements, or (iii) shift to the
payment structure described in the following clause (c).  (c)           Minimum
Product Purchase.  At any time
during the Term of this Agreement, the parties may mutually agree in writing to
shift from the payment structure described in Section 2.4 (a) or 2.4(b), as
applicable, to the structure described in this Section 2.4(c).  Upon such agreement (i) NeoRx will guarantee
to University that it will purchase a minimum of seventy-five (75) Curies of
Product per week (the Minimum Purchase Requirement), and must purchase such
Minimum Purchase Requirement during the remainder of the Term  and (ii) the University will be capable of
Producing a single 120 Ci batch on any single day for delivery on Monday (or as
otherwise mutually agreed upon each week) in time to meet NeoRxs shipping
requirements (as set forth in section 2.3 (a)). .  From time to time thereafter during the Term of this Agreement,
the parties may agree in writing to adjust upward the Minimum Purchase
Requirement and the Universitys Production Capacity..  Upon agreeing to adjust the Minimum Purchase
Requirement, NeoRx will be obligated to continue to purchase no less than such
minimum number of Curies during the remainder of the Term.  Once the parties elect the payment structure
described in this Section 2.4 (c), the Minimum Monthly Fee described in Section
2.4(a) (or under Section 2.5(b) if the parties have agreed to an increase in
such fee) shall no longer apply and NeoRx may not elect to revert back to the
payment structure described in Section 2.4(a) or 2.4(b).  (d)           Notwithstanding
the above provisions, NeoRx will not be obligated to make payment for any
Curies that NeoRx fails to take delivery of as a result of the Universitys
inability to make the Product available to NeoRx.  2.5          Universitys Production Capacity  (a)           Minimum
Production Capacity: Subject to the terms and conditions of this Agreement,
University will be capable of Processing, and NeoRx will have the right to
purchase 60 Curies of Product per calendar week on an ongoing basis throughout
the Term (the Minimum Production Capacity) with the University being capable
of Processing a single 60 Ci batch on any single day for delivery on Monday (or
as otherwise mutually agreed upon each week) in time to meet NeoRxs shipping
requirements (as set forth in section 2.3 (a)).  The Parties agree that the Minimum Production Capacity
will be based on the calculated activity level at Calibration Time.  The Parties acknowledge that although NeoRx
will  6 
   be obligated to make applicable minimum payments to University as
described in Section 2.4, NeoRx is not obligated to take delivery of the Curies
available within the Universitys 
Production capacity and that the actual number of Curies University will
Process and ship per calendar week will be dependent on the Purchase Orders
University receives from NeoRx.  (b)           Shipping
Capacity: University shall be obligated to ship a maximum of one (1) type B
package per Monday to Denton, Texas. 
University shall be additionally obligated to provide up to a maximum of
twelve (12) type A packages per week on Monday afternoon and Tuesday afternoon,
with a maximum of six (6) per day.  2.6          Responsible Personnel  During the Term of this Agreement, University will
staff the Processing of the Product with personnel who are reasonably qualified
consistent with industry standards. 
University will name a person responsible for production and a person
responsible for quality assurance.  The
person responsible for quality assurance and the person responsible for
Production will in no event be the same person.  If any person named by University terminates his or her
employment with University during the Term of this Agreement, University shall
replace that individual as soon as possible with someone of a comparable level
of experience.  2.7          Waste Disposal  University shall be responsible for the disposition,
in accordance with all established regulations, of all Waste generated at
University.  ARTICLE III - DELIVERY & TITLE 3.1          Delivery  All Product purchased by NeoRx hereunder shall be
delivered F.O.B. Facility.  Risk of loss
and title to the Products shall pass to NeoRx upon delivery to and receipt by
NeoRxs designated carrier.  3.2          Shipping Charges  NeoRx, in consultation with University, shall arrange
for the shipment of the Product from the Universitys dock.  NeoRx shall be responsible for the payment
of all shipping charges associated with such shipments.  NeoRx shall make all third-party payment
directly.  3.3          Inspection and Acceptance  (a)           Product
Conformance: All Product shall comply with the Release Specifications.  In accordance therewith, each Batch of
Product delivered to NeoRx shall be accompanied by or promptly followed by a
Certificate of Analysis relating to such Batch.  NeoRx may reject any Batch if University fails to comply with
Release Specifications or fails to deliver a Certificate of Analysis along with
such batch.  If NeoRx rejects a Batch
for such reasons, NeoRx may return such Batch to University (at Universitys
cost).  NeoRx shall not be obligated to
pay for such  7 
   rejected Batch (and shall  not
be obligated to pay for any shortfall below the Minimum Quantity resulting from
such rejected Batches)  (b)           Disputes
Regarding Conformance Of A Batch Of Product:The parties agree to select a mutually agreeable independent
laboratory as soon as possible after the effective date of this agreement to
assist in resolving disputes regarding product conformance.  A sample of the batch of product in dispute
will be submitted from University to the independent lab for analysis.  If the laboratory concludes that the product
is not in conformance as set forth in subsection (a) above, the University
shall pay for the analysis and reimburse NeoRx in accordance with subsection
(a) above.  Otherwise, NeoRx shall pay
for the analysis and accept the batch.  3.4          Shipping Containers  NeoRx has developed a design for a shipping container
(Container Design) to be used for the shipment of radiopharmaceutical
products.  University owns a number of
depleted uranium containers (the DU Containers), which are necessary to ship
radiopharmaceutical products.  NeoRx
agrees to license the use of the Container Design to University for the
Universitys own internal use on a perpetual, limited, non-exclusive,
non-transferable, royalty free basis with no right to sub-license in return for
University allowing NeoRx to use six (6) DU Containers, free of charge, during
the Term for all orders of the Product. 
The DU Containers loaned to NeoRx under this Agreement are to be used
solely for transport of radioactivity within MURR or shipment of radioactivity
as mutually agreed by NeoRx and the University.  NeoRx shall remain the sole owner of the Container Design and
University shall remain the sole owner of all DU Containers; provided, however,
that upon termination of this Agreement NeoRx will have the option to lease the
six (6) DU Containers for one (1) year after termination of the Agreement at a
commercially reasonable rental rate.  ARTICLE IV  PURCHASE 
PRICE AND PAYMENT 4.1          Initial Payment  The Parties acknowledge that NeoRx will make a
one-time cash payment to University of Four HundredThousand Dollar (US $400,000) (the Initial
Payment) for costs incurred in preparing to provide serviceson
signing this Agreement.  [*] will be paid by December 31, 2001.  The remaining [*] will be paid by May 31, 2002.  4.2          Curie Fee  (a)           Under
Minimum Monthly Fee.  NeoRx will pay
to University a per Curie fee for Product of [*]
per Curie (measured at shipping time) for each Curie purchased in any month in
excess of the amount covered by the Minimum Monthly Fee described in Section
2.4(a) (or 2.4(b) if applicable).  The
price for each Curie covered by the Minimum Monthly Fee (whether [*] pursuant to Section 2.4(a) or increased
pursuant to Section 2.4(b)) shall be [*]/Ci
(at shipment time).  (b)           Under
Minimum Product Purchase.  If the
parties mutually agree that NeoRx will Guarantee a minimum of 75 Ci/week as
described in section 2.4.(c), the per Curie fee based on  8 
   the price list set forth on Exhibit B will be applied for the duration
of the Term.  Any subsequent adjustment
to the Minimum Purchase Requirement may have an effect on the per Curie price
payable by NeoRx to be agreed upon by the parties, which effect will be described
in an amendment to Exhibit B.  (c)           Basis
for Curie Fees.  The Parties agree
that the prices set forth in section 4.2(a) above are based on the calculated
total Curie content in the Product at the time the Product departs from
Universitys shipping docks (or upon internal delivery to ABC Laboratories,
Inc.), and that the Curie Fee includes the cost of labor, materials, cost of
the Dedicated Equipment and overhead to Process, including testing the finished
Product and is exclusive of the cost of shipping, and packaging and handling
expenses.  The total Curie content in
the Product will be determined as described in the Standard Operating Procedure
for total activity level.  ARTICLE V - REGULATORY MATTERS  5.1          General  University understands that it will be primarily
responsible for ensuring that the Facility and the Process will be cGMP
compliant as required by the FDA. 
University will (a) create the Master Batch Record and Standard
Operating Procedures, which University will comply with in Processing the Product
(in addition to complying with the Release Specifications), (b) maintain all
required regulatory documents covering the Process and the Facility, and (c)
make all such required documents available to NeoRx for its review upon NeoRxs
request.  5.2          New Drug Applications  University shall cooperate with NeoRx with respect to
any NDA obligations relating to the Product that are imposed by the FDA or
foreign regulations.  NeoRx shall be
responsible for obtaining FDA or other regulatory approval for the NDA for any
drug products utilizing the Product, and shall own the NDA.  University agrees to comply with all
commitments made in the NDA regarding Universitys Processing responsibilities,
but NeoRx agrees not to make commitments to the FDA on behalf of the University
without the Universitys prior written approval.  5.3          Master File  University agrees to file its Product related drug
master file (MF) by the time NeoRx files its NDA.  University agrees that it will provide NeoRx information
necessary for NeoRx to respond to any inquiries from the FDA.   University agrees that it will not make
material changes to its (a) raw materials supplier, (b) materials
specifications, (c) formulation process, (d) formulation equipment, or (e)
testing procedures without prior written notification to NeoRx in order to give
NeoRx an opportunity to validate that such changes would have no negative
impact on the Product.  9 
   5.4          Notice of Safety Related Information  MURR and NeoRx shall provide to each other prompt notice
of any information it receives relating to the safety of the Product, including
any confirmed or unconfirmed information on adverse, serious, or unexpected
events associated with the use of the Product. 
For serious (based on a good faith evaluation), unexpected events, MURR
and NeoRx shall give each other notice by telephone within one (1) business day
after receipt of the information and followed by written notice not less than
one (1) week thereafter.  The Parties
shall cooperate in responding to all applicable governmental agencies and
filing any reports with such agencies concerning any reactions (including drug
experience reports) caused by the Product. 
The Parties shall cooperate in providing timely assistance in responding
to any complaints relating to commercial goods produced and sold by NeoRx that
contain Product.  The costs associated
with responding to such complaints shall be borne by NeoRx; provided, however,
if the complaint was directly or indirectly caused by Universitys failure to
Process the Product in strict accordance with the Master Batch Record or
Release Specifications, University shall reimburse NeoRx for all reasonable
internal and external costs and expenses incurred by NeoRx to appropriately
respond to such complaints (up to a maximum of [*] per production batch).  ARTICLE VI - RECORDS AND AUDITS  6.1          Batch Records  University will create the Master Batch Record and
related documentation which must conform to all FDA requirements and other
applicable laws and regulations.  During
the Term of this Agreement, and for five (5) years after NeoRxs receipt of any
particular Batch of Product from University, University shall maintain records
relating to such Curie sufficient to substantiate and verify that University
met its duties and obligations under this Agreement.  Such records shall include, but not be limited to, records of
orders received, raw materials purchased and stored, Batch Records for Product
manufactured, work in progress, Processing analyses and release control tests
and the like.  6.2          Agency Records and Audits  University shall make available to NeoRx and all
applicable government agencies all documents and updates that they have
prepared with regard to Processing the Products that are required by law to be
filed with any governmental agency. 
University shall submit to all inquiries and inspections by any
governmental agency with authority to conduct such inquiries and inspections
(hereinafter collectively referred to as Agency).  University shall promptly notify NeoRx of any Agency interactions
and/or correspondence relating to Universitys operations that could relate,
directly or indirectly, to the Product. 
University shall make available for inspection by NeoRx all documents
and correspondence received from any Agency that relate in any way to the
Process or the Product.  University
shall immediately inform NeoRx of all Agency audits that relate in any way to
the Process or the Product.  Similarly,
NeoRx shall inform University in advance of any Agency planned audits of NeoRx
if such audits relate directly to the Products.  University shall immediately provide NeoRx with copies of any
regulatory letters or other documents issued by any Agency and received by
University in connection with the audit or any inspection relating to the
Product.  10 
   6.3          FDA  NeoRx shall obtain and maintain all FDA and other
regulatory approvals necessary to enable NeoRx to use the Products as intended
under this Agreement.  University shall
cooperate with NeoRx as required in order to secure and maintain such
governmental and other approvals.  6.4          Inspections  University shall permit indoctrinated employees and/or
representatives of NeoRx to enter and conduct a reasonable inspection and/or
audit of the Facility and/or the documents associated with the Processing of
Product during normal business hours and with at least seventy-two (72) hours
advanced notice in order to determine whether the Products are being Processed
in conformity with the terms of this Agreement.  In addition, and in conformity with all applicable laws, rules
and regulations, University shall permit employees or representatives of NeoRx
to inspect Products designated for delivery to NeoRx and otherwise provide
NeoRx with such information as it may reasonably be required to determine
whether the Products are being Processed in accordance with this Agreement,
including without limitation in accordance with the Master Batch Record,
Standard Operating Procedures, and all applicable laws, rules and regulations.  ARTICLE VII - REPRESENTATIONS AND WARRANTIES  7.1          Labor and Equipment  University represents that it shall furnish all labor,
equipment and facilities necessary to Process Product in the amounts, and in
the timely manner, as set forth in each Purchase Order.  University has obtained, and will maintain
throughout the Term, all licenses necessary to Process the Product.  University will abide by all applicable
rules, regulation, laws and mandates issued by all applicable regulatory
bodies.  7.2          Processing Requirements  University represents, warrants and agrees that it
will Process all of the Product in strict accordance with this Agreement,
including without limitation (i) the Master Batch Record, (ii) the Standard
Operating Procedures,(iii) the Release Specifications, (iv) all federal, state
and local laws, statutes, regulations or other requirements relating thereto
and applicable to the intended use of such Product, and (v) the Master File
(once submitted to the FDA).University further represents that it is not a
party to any other agreement that could hinder its ability to fulfill its
obligations under this Agreement.  7.3          Records Relating to Waste Disposal  University represents that it shall obtain and
maintain all waste generator licenses, disposal manifests and other records in
accordance with Federal statutes, laws and regulations and the statutes, laws
and regulations of the State of Missouri.  11 
   7.4          Changes  University agrees that it will not implement any
material revisions or changes to the Product, Process, Master Batch Record or
Standard Operating Procedures associated with Universitys Processing of the
Product for and on behalf of NeoRx without prior written notification to NeoRx
in order to give NeoRx an opportunity to validate that such changes would have
no negative impact on the Product.  A
material revisions or changes means any revision or change that would impact
(a) the raw materials supplier, (b) materials specifications, (c) formulation
process, (d) formulation equipment, or (e) testing procedures   Furthermore, University will not make any
changes, material or otherwise, to the Release Specifications without prior
written approval of NeoRx.  7.5          Safety Procedures  University represents that it shall have primary
responsibility for adopting and enforcing safety procedures for the handling
and production of the Products that comply in all material respects with all
federal, state and local environmental and occupational safety and health
requirements to which University is subject.  ARTICLE VIII - CONFIDENTIAL INFORMATION  8.1          Limitations on Disclosures  Except to the extent expressly authorized by this
Agreement, during the Term of this Agreement and for five (5) years thereafter,
neither Party shall:  (a)           disclose,
publish, or make available any Proprietary Information disclosed to it by the
other to any third party, including employees who do not need to know or have
access to such Proprietary Information; or  (b)           sell,
transfer, or otherwise use or exploit any such Proprietary Information
disclosed to it by the other Party; or  (c)           knowingly
permit the sale, transfer, use or exploitation by a third party of any such
Proprietary Information which may have been disclosed to such third party,
including employees who do not need to know or have access to such Proprietary
Information.  During the Term of this Agreement, neither Party shall
make any press release or other disclosure of the terms of this Agreement
without the prior written consent of the other Party, except as required by law
or bya
court of competent jurisdiction and pursuant to the disclosure requirements of
federal or state regulatory agencies, including the United States Securities
and Exchange Commission.  8.2          Use of Parties Names  Neither Party shall advertise any connection with the
other Party nor make use of the other Partys name or other identifying marks
or property, nor make representations, either  12 
   express or implied, without the other Partys prior written
approval.  The prior sentence shall not,
however, be construed so as to prevent mention of the contribution of either
Party in any scientific publication.  8.3Scholarly Publications  Notwithstanding paragraph 8.1(b) University shall have
the right to publish in scholarly journals and make scholarlypresentations
concerning any information it may develop as a result of this Agreement.  University shall provide NeoRx with a copy
of any proposed scholarly publication or presentation 45 days before submission
for publication or presentation to allow NeoRx to review and comment on the
publication or presentation and delete any confidential Proprietary Information
of NeoRx.  NeoRx may request a 60 day
delay of the publication or presentation to allow the preparation of patent
applications should the materials disclose an invention.  ARTICLE IX - INDEMNIFICATION  9.1          Indemnification  (a)           Subject
to Section 9.2, NeoRx shall defend, indemnify, and hold harmless University,
its officers, agents, employees and Affiliates from any third-party loss,
claim, action, damage, expense or liability (including defense costs and
reasonable attorneys fees) arising out of NeoRxs (a) breach, violation or
nonfulfillment of any of its covenant, agreements, representations or
warranties under this Agreement, (b) handling, possession, or use of the
Products after Universitys delivery of the same to NeoRx, (c) negligence or
willful misconduct, or (d) breach of any third partys trade secret rights,
except to the extent that such loss, claim, action, damage, expense or
liability is based on, arises out of, or is due to the negligence or willful
misconduct of, or breach of this Agreement by, University.  (b)           Subject
to Section 9.2, to the extent permitted by Missouri law and without waiving
sovereign immunity, University shall defend, indemnify, and hold harmless
NeoRx, its officers, agents, employees and Affiliates from any third-party
loss, claim, action, damage, expense or liability (including defense costs and
reasonable attorneys fees) arising out of Universitys (a) breach, violation
or nonfulfillment of any of its covenant, agreements, representations or
warranties under this Agreement, (b) handling, possession, or use of the
Products prior to Universitys delivery of the same to NeoRx, (c) negligence or
willful misconduct, (d) disposal of any Waste, or (e) breach of any third
partys trade secret rights, except to the extent that such loss, claim, action,
damage, expense or liability is based on, arises out of, or is due to the
negligence or willful misconduct of, or breach of this Agreement by, NeoRx.  9.2          No Personal Liability  No shareholder, member, officer, employee or board
member (the Individuals), individual or collectively, of either University or
NeoRx incurs or assumes any individual or personal liability by the execution
of this Agreement or by reason of the default of either Party in  13 
   the performance of any of the terms herein.  All such liability of the Individuals of each Party is hereby
released by the other Party as a condition of and in partial consideration for
the execution of this Agreement.  9.3          Procedure  Each Party agrees to give to the indemnifying Party
(a) prompt notice of any claim or suit coming within the purview of the
indemnities contained in this Article IX, (b) all relevant facts in its
possession or control, subject to the treatment of such information pursuant to
Article VIII, (c) the right to exclusive control of the defense of any action
(at its sole expense), and (d) its cooperation in the defense of any such
action.  ARTICLE X - TERM AND TERMINATION  10.1        Term  (a)           Subject
to the Parties ability to terminate this Agreement as set forth in this
Article X, the Initial Term of this Agreement shall commence on the Effective
Date and shall continue through December 31,2002 (the Initial Term).  (b)           NeoRx
shall have the option to renew this Agreement, with the consent of the
University which will not be unreasonably withheldunder the same terms and
conditions, for one (1) additional twelve (12) month term (the Extension
Term); provided, that NeoRx shall exercise its option, if at all, in writing
with no less than ninety (90) days remaining in the Initial Term.  The Initial Term and Extension Term, if any,
unless terminated earlier pursuant to the terms of this Agreement, are referred
to herein as the Term.  (c)           Notwithstanding
clauses (a) and (b) above, the Parties acknowledge that at any time they may
agree to replace this Agreement in its entirety with a long-term commercial
supply agreement.  10.2        Termination by Either Party  Either Party may terminate this Agreement at any time
after the happening of any of the following events; provided, however, that the
Party terminating this Agreement shall provide the other with written notice of
such termination prior to the date thereof:  (a)           either
Party breaches any of its agreements, covenants, representations or warranties
as set forth in this Agreement and the breaching Party fails to cure such
breach within fifteen (15) days of written notice thereof from the
non-breaching Party; or  (b)           University
fails to timely fulfill three (3) or more Purchase Orders in any calendar
quarter; or  (c)           the
FDA (or other governmental agency with authority), Missouri Department of
Health or other regulatory agency orders University to cease Processing the
Product or orders NeoRx to permanently cease utilizing the Product.  14 
   Notwithstanding any provision in this Agreement to the
contrary, University shall continue to Process the Product, and deliver Product
in response to any Purchase Order, through the date of termination, unless such
Process and delivery requirements are waived in writing by NeoRx.  10.3        Disputes  In the event of a dispute regarding the interpretation
of this Agreement, the Parties agree they will endeavor to resolve such dispute
amicably.  In the event a dispute cannot
be resolved by the Parties, then upon the written request of any Party that
includes a summary of the dispute, a senior executive officer of NeoRx and a
senior official of MURR shall promptly meet and endeavor to resolve the dispute
through good-faith negotiations within thirty (30) days of their receipt of the
dispute.  10.4        Return of Information  Upon expiration or termination of this Agreement, each
Party shall return all originals and copies the other Partys Proprietary
Information it may have received or created.   10.5        Rights on Termination  (a)           Continuing
Obligations.  Upon termination of
this Agreement, each of the Parties shall continue to be bound by its
obligations under Articles VII, VIII and IX of this Agreement.  (b)           NeoRxs
Additional Remedies.  If NeoRx
terminates this Agreement pursuant to Section 10.2(a) (for Universitys breach
of this Agreement) or Section 10.2(b) (for Universitys failure to timely
fulfill Purchase Orders), then, in addition to any other remedy available to
NeoRx at law:  (i)            during
the six (6) months following termination, if requested by NeoRx University
shall provide not more thanone hundred and twenty (120) person-hours
of the time of University employees, at no additionalcost to NeoRx, to facilitate
a transition toa third party facility for Processing the Product  (ii)           within
thirty (30) days of such termination, University shall transfer to NeoRx
certified copies of all Lot Files relating to batches of Product delivered to
NeoRx.. and  (iii)          University
will, at NeoRxs request, continue to Process Product pursuant to the terms and
conditions of this Agreement and sell the same to NeoRx at the prices in effect
at time of termination for the remainder of the Term.  ARTICLE XI - FORCE MAJEURE  Neither Party hereto shall be liable to the other in
damages for, nor shall this Agreement be terminable by reason of, any delay or
default in such Partys performance hereunder if such delay or default is
caused by conditions beyond such Partys control including, but not limited to,
acts of God, war, insurrection, civil commotion, destruction of production
facilities or materials  15 
   by earthquake, fire, flood or storm, labor disturbances including
strikes or lockouts or epidemic (Force Majeure).  Each Party hereto agrees to promptly notify the other Party of
any event of Force Majeure and to employ all reasonable efforts toward prompt
resumption of its performance hereunder when possible if such performance is
delayed or interrupted by reason of such event.  ARTICLE XII - MISCELLANEOUS  12.1        Assignment  This Agreement shall be binding upon and inure to the
benefit of the Parties, their successors and permitted assigns.  Notwithstanding the foregoing, NeoRx may
assign its rights and/or delegate its obligations under this Agreement to any
third party. NeoRx will give University immediate notice of any such
assignment.  University may not assign
its rights and/or delegate its obligations under this Agreement to any third
party without NeoRxs prior written consent.  12.2        Entire Agreement; Amendments;
Counterparts  This Agreement, along with each Purchase Order and the
attached Exhibits, contains the entire understanding of the Parties hereto
relating to the subject matter contained herein, supersedes all prior
agreements, promises and understandings of the Parties.  This Agreement may not be modified, amended
or any provision waived except by written agreement of the Parties.  This Agreement may be executed in
counterparts, each of which shall be deemed to be an original and all of which
together shall constitute one and the same agreement.  12.3        Notices  All notices, demands, requests and other
communications shall be in writing or by written telecommunication, and shall
be given when delivered personally to the addressee or, if mailed, by certified
mail, return receipt requested, postage prepaid, or sent by written
telecommunication, when delivered to the addresses specified below.  Either Party may from time to time change
its address, facsimile number or designated individual by notice to the other
Party.  If to NeoRx:
  NeoRx Corporation410 West Harrison StreetSeattle, Washington 98119-4007Attention: Becky BottinoIf to University:Attention:  Such notice, demand, request, and other communications
shall be deemed to have been given as of the date so delivered or transmitted
by facsimile (as long as the transmitting machine confirms successful
transmission) or, if mailed, three (3) business days after the date so mailed,
or, if sent by overnight courier service, one (1) business day after the date
so sent.  16 
   12.4        Relationship of Parties  The Parties are acting herein as independent
contractors and independent employers. 
Nothing herein contained shall create or be construed as creating a
partnership, joint venture, joint employer or agency relationship between the
Parties and no Party shall have the authority to bind the other in any respect.  12.5        No Waiver; Severability  Any provision of this Agreement may be waived at any
time in writing executed by the Party for whose benefit such provision exists;
provided, however, that the failure to enforce any provision of this Agreement
shall not constitute a waiver thereof. 
In the event that any provision of this Agreement shall be held invalid
or unenforceable under applicable law, the remainder of this Agreement shall
remain valid and enforceable, unless such invalidity or unenforceability
substantially diminishes the rights and obligations, taken as a whole, of any
Party.  12.6        Agreement Approval; Further Assurances  Each Party hereby represents and warrants that all
necessary corporate approvals for this Agreement have been obtained, and the
person whose signature appears below has the authority necessary to execute
this Agreement on behalf of the Party indicated.  Each Party agrees that it shall execute such further documents
and perform such further acts as may be necessary to comply with the terms of
this Agreement.  12.7        Captions  The captions in this Agreement are solely for
convenience of reference and shall not be used for purposes of interpreting or
construing the provisions hereof.  12.8        Intellectual Property  No trademark, trade name, logo, trade dress, copyright
or license therein, or other intellectual property rights (collectively,
Intellectual Property) are conveyed by this Agreement, and neither Party
shall have the right to use the other Partys Intellectual Property for any
purpose whatsoever without prior written consent.  12.9        Survival  The provisions in Article VII, VIII, IX and XII, and
Sections 2.8, 3.4, 6.1, 10.3, 10.4 and 10.5, shall survive the termination of
this Agreement.  IN WITNESS WHEREOF, the Parties have caused this
Agreement to be executed by duly their authorized representatives, effective on
this date first set forth above.  17 
   THE
  CURATORS OF THE UNIVERSITY
  OF MISSOURI
  NEORX
  CORPORATIONBy:
  
  By:Name:
  
  Name:Its:
  
  Its:
  18 
   EXHIBIT A
RELEASE SPECIFICATIONS  Release Specifications for 166HoCl3  Tests
  
  Methods
  
  SpecificationsHolmium quantitation
  
  Calculated based on
  target mass and 
  recovered activity
  
  [*]Activity concentration
  
  Calculated from Total
  Activity and 
  Volume
  
  [*]Specific Activity
  
  Calculated from
  activity concentration 
  and holmium quantitation
  
  [*]Radionuclidic purity
  
  Gamma ray spectroscopy 
  Ho1-Q053
  
  [*]Identification
  
  Gamma ray spectroscopy 
  Ho1-Q053
  
  [*]Radiochemical purity
  
  ITLC  SG 
  Ho1-Q052
  
  [*]
  
 *Calibration time is 12 Noon CST, the day of shipment.  19 
   EXHIBIT B PER CURIE PRICE LIST 75 Ci/WEEK
GUARANTEE*  **  Curies Per
  Week
  Purchase Level*
  
  Price
  Per CurieFirst 100
  
  [*]Next 50
  
  [*]Next 50
  
  [*]Next 100
  
  [*]  For example, if NeoRx purchases 170 Curies of Product
in a given week, the price for that week would be:  100 x  [*]50   x  [*]20   x  [*]Weeks total: [*] 
  *              If the parties
agree to increase the Minimum Purchase Requirements, the scale will be adjusted
accordingly.  For example, if NeoRx
guarantees 101 Ci/week, the first 150 Curies will be at [*], the next 50 at [*] and the next 100 at [*].  20